Regulatory Affairs Services Provider in Sweden
DDReg provides regulatory affairs services in Sweden for pharmaceutical, medical device, biologics, and ATMP companies. Our consultants manage MPA (Läkemedelsverket) submissions across national and EU network procedures, coordinate TLV reimbursement applications, and maintain post-authorisation compliance for products throughout the Swedish market lifecycle.
Regulatory Authorities in Sweden
The Medical Products Agency (MPA; Swedish: Läkemedelsverket) is the single competent authority in Sweden responsible for regulating medicinal products, medical devices, and cosmetics. The MPA operates under the Swedish Ministry of Health and Social Affairs and is funded primarily through applicant fees. Approximately 750 staff the majority pharmacists and physicians carry out assessment, inspection, and surveillance functions.
The primary legislative basis is the Medicinal Products Act (2015:315, Sw. läkemedelslagen) and the Medicinal Products Ordinance (2015:458). Clinical trials are governed directly by EU Regulation 536/2014 (CTR). Medical devices fall under EU MDR 2017/745 and IVDR 2017/746, supplemented by Sweden's Act (2021:600) and Ordinance (2021:631).
The MPA holds one of the strongest records among EU national competent authorities for scientific engagement. Over the last five years it has ranked in the top three EU agencies by volume of centralized procedures managed and provides expert assessors to over 110 working groups and committees within EMA and the Heads of Medicines Agencies (HMA) network. The MPA is consistently selected as Reference Member State (RMS) in mutual recognition and decentralised procedures historically the most frequently chosen RMS in Europe.
Regulatory Authorities Framwork in Sweden
| Authority | Role |
|---|---|
| MPA (Läkemedelsverket) | Single competent authority for medicinal products, medical devices, and cosmetics; grants national marketing authorisations; approves clinical trials; conducts GMP inspections; leads pharmacovigilance surveillance |
| TLV (Tandvårds- och läkemedelsförmånsverket) | Dental and Pharmaceutical Benefits Agency; determines reimbursement eligibility and approved retail price for out-patient medicines under the pharmaceutical benefits scheme |
| NT Council (NT-rådet) | New Therapies Council; issues national recommendations on hospital and specialist medicines, ATMPs, and high-cost inpatient therapies on behalf of Sweden's 21 regions |
| EMA | EU central authority; MPA provides Swedish assessors to CHMP, PRAC, CVMP, and CAT; mandatory for ATMPs, biotechnology products, and certain new active substances |
| Swedish eHealth Agency | Maintains the VARA national product register; coordinates NPL identifiers used by TLV, MPA, pharmacies, and prescribing systems |
Regulatory Affairs Consulting Sweden - Services Portfolio
DDReg's pharmaceutical regulatory affairs Sweden practice covers the full product lifecycle across medicinal products, medical devices, biologics, and advanced therapies.
-
Marketing Authorisation - Pharmaceuticals
-
Clinical Trials
-
Medical Devices and IVDs
-
Biologics and Advanced Therapy Medicinal Products (ATMPs)
-
Post-Approval Lifecycle Management
Sweden Regulatory Approval Timelines
Assessment timelines follow EU regulatory framework standards. Clock stops for applicant responses are excluded from the active assessment period:
| Procedure | Assessment Period |
|---|---|
| National Procedure (pharmaceuticals) | 210 days (excl. clock stops); 14-day prior validation |
| Mutual Recognition Procedure - RMS phase | 90 days |
| Mutual Recognition Procedure - CMS phase | 90 days |
| Decentralised Procedure (DCP) | 210 days (RMS + CMS combined) |
| Centralised Procedure (EMA) | 210 days (CHMP opinion) |
| Type IA variation | 30 days (notification; may implement immediately in some cases) |
| Type IB variation | 30 days (assessment) |
| Type II variation | 60 days (up to 90 with extension) |
| Medical devices - Class I (CE marked) | MPA registration within days of EEA market placement |
| Medical devices - Class IIa/IIb (CE marked) | Notified body dependent; typically, 3–9 months |
| Medical devices - Class III (CE marked) | Notified body dependent; typically, 6–18 months |
| TLV out-patient reimbursement decision | 180 days from complete application |
Note: Clock stop periods for List of Questions and List of Outstanding Issues responses add to calendar time. Complete, well-prepared submissions minimise clock-stop frequency. The MPA does not accept partial or staged responses.
Why Choose DDReg for Regulatory Affairs Services in Sweden ?
Our consultants understand MPA's structured assessment timeline - the two clock-stop windows at Day 110 and Day 165, the strict complete-response requirement, and the Day 195 resolution deadline. This knowledge shapes dossier preparation and response strategy to reduce clock-stop frequency and duration.
DDReg manages procedures where Sweden functions as RMS, from Day 0 briefing preparation through the national assessment report and CMDh coordination. Our team handles Concerned Member State question lists, divergent position resolution, and simultaneous national approval management across participating EEA countries.
EU procedure dossiers submit in English. Module 1 national elements - including the patient information leaflet (PIL), proposed SmPC, and labelling - require Swedish. DDReg provides Swedish-language regulatory writing, and coordinates VARA register submissions through MPA's LiiV system.
MPA authorisation does not include TLV reimbursement or NT Council recommendation. For most out-patient Rx products, commercial viability requires TLV inclusion in the pharmaceutical benefits scheme. DDReg coordinates health economic dossier preparation, manages TLV application timing relative to MPA approval, and supports NT Council benefit submissions for hospital and specialist products - including ATMPs where managed entry agreements are increasingly required.
Sweden's standing in EMA scientific committees provides distinct advantages for companies pursuing the centralized procedure. DDReg assesses whether Swedish MPA rapporteur or co-rapporteur positioning is achievable and advantageous for a given programme, and coordinates accordingly with EMA procedure management teams.
Global Reach Explorer
Find Your Solution
Our Regulatory Affairs Consulting Services in Sweden portfolio covers:
Regulatory Strategies
The pharmaceutical industry operates under stringent regulations to ensure the safety, efficacy, and quality...
New Product Marketing Authorizations
Navigating marketing authorization is a complex and time-sensitive process. Every country has its own regulatory framework...
Gap Analysis and Remediation
In the highly regulated pharmaceutical industry, maintaining compliance is critical. Regulatory gap analysis helps identify deficiencies in technical documentation...
Regulatory Due Diligence
Regulatory issues arise unexpectedly and can create significant strain on a company’s resources. As such, it is advisable for all companies to carry out regular and frequent regulatory due diligence and audits...
API & DMF services
Drug Master Files (DMFs) contain confidential and detailed information regarding API processes—from manufacturing to storage. DDReg’s DMF Services deliver precise...
CMC Advisory
DDReg’s CMC services are dedicated to assisting customers in developing robust and an efficient regulatory strategy through all development phases - authoring...
Post Approval Life Cycle Management
Maximize product value with expert pharma lifecycle management. Our dedicated team ensures that your product remains on shelves and compliant with ever-evolving regulations through strategic post-approval management...
Certification Services
Partner with DDReg to navigate the complex process of regulatory certification of pharmaceutical...
ANDA and MA Holder Services
Our comprehensive services support both Abbreviated New Drug Applications (ANDA) and Marketing Authorization processes.
Publishing & Submission
Our comprehensive digital solution transforms traditional paper dossier submissions into a streamlined electronic format. With robust infrastructure and cutting‐edge management processes...
